Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

被引：73

作者：

Hitz, Felicitas ^{[1
,2
,5
]}

Connors, J. M. ^{[2
]}

Gascoyne, R. D. ^{[2
,3
,4
]}

Hoskins, P. ^{[2
]}

Moccia, A. ^{[2
,5
]}

Savage, K. J. ^{[2
]}

Sehn, L. H. ^{[2
]}

Shenkier, T. ^{[2
]}

Villa, D. ^{[2
]}

Klasa, R. ^{[2
]}

机构：

[1] Kantonsspital St Gallen, Med Oncol, Oncol Haematol, CH-9007 St Gallen, Switzerland

[2] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] British Columbia Canc Agcy, Div Pathol, Vancouver, BC V5Z 4E6, Canada

[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[5] Ist Oncol Svizzera Italiana, Bellinzona, Switzerland

来源：

ANNALS OF HEMATOLOGY | 2015年 / 94卷 / 11期

关键词：

Primary refractory; Diffuse large B cell lymphoma; R-CHOP; Comorbidity; NON-HODGKINS-LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; ELDERLY-PATIENTS; TRANSPLANTATION; REGIMENS;

D O I：

10.1007/s00277-015-2467-z

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Primary refractory diffuse large B cell lymphoma (DLBCL) following R-CHOP chemotherapy is a major concern. We identified 1126 patients with DLBCL treated with R-CHOP from 2000 to 2009, of whom 166 (15 %) had primary refractory disease. Of the 75/166 (45 %) who were age < 70 years and had been planned for stage-directed curative therapy, 43 (57 %) were primary nonresponders and 32 (43 %) relapsed within 3 months of completing R-CHOP. Thirty of 75 (40 %) patients had serious comorbidity and organ dysfunction precluding intensive treatment and had palliative treatment only. Twelve of 45 (27 %) patients responded to second-line treatment and underwent ASCT. The median overall survival for the 75 patients was 10 months with only seven patients alive without evidence of disease at follow-up ranging from 14 to 106 months. Primary refractory DLBCL after R-CHOP has a very poor outcome with only anecdotal survivors independent of the intended treatment approach.

引用

页码：1839 / 1843

页数：5

共 15 条

[1]

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma [J].

Aukema, Sietse M. ;

Kreuz, Markus ;

Kohler, Christian W. ;

Rosolowski, Maciej ;

Hasenclever, Dirk ;

Hummel, Michael ;

Kueppers, Ralf ;

Lenze, Dido ;

Ott, German ;

Pott, Christiane ;

Richter, Julia ;

Rosenwald, Andreas ;

Szczepanowski, Monika ;

Schwaenen, Carsten ;

Stein, Harald ;

Trautmann, Heiko ;

Wessendorf, Swen ;

Truemper, Lorenz ;

Loeffler, Markus ;

Spang, Rainer ;

Kluin, Philip M. ;

Klapper, Wolfram ;

Siebert, Reiner .

HAEMATOLOGICA, 2014, 99 (04) :726-735

[2]

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[3]

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:: A study by the groupe d'Etude des lymphomes de l'adulte [J].

Feugier, P ;

Van Hoof, A ;

Sebban, C ;

Solal-Celigny, P ;

Bouabdallah, R ;

Fermé, C ;

Christian, B ;

Lepage, E ;

Tilly, H ;

Morschhauser, F ;

Gaulard, P ;

Salles, G ;

Bosly, A ;

Gisselbrecht, C ;

Reyes, F ;

Coiffier, B .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4117-4126

[4]

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].

Gisselbrecht, Christian ;

Glass, Bertram ;

Mounier, Nicolas ;

Gill, Devinder Singh ;

Linch, David C. ;

Trneny, Marek ;

Bosly, Andre ;

Ketterer, Nicolas ;

Shpilberg, Ofer ;

Hagberg, Hans ;

Ma, David ;

Briere, Josette ;

Moskowitz, Craig H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190

[5]

Stromal Gene Signatures in Large-B-Cell Lymphomas [J].

Lenz, G. ;

Wright, G. ;

Dave, S. S. ;

Xiao, W. ;

Powell, J. ;

Zhao, H. ;

Xu, W. ;

Tan, B. ;

Goldschmidt, N. ;

Iqbal, J. ;

Vose, J. ;

Bast, M. ;

Fu, K. ;

Weisenburger, D. D. ;

Greiner, T. C. ;

Armitage, J. O. ;

Kyle, A. ;

May, L. ;

Gascoyne, R. D. ;

Connors, J. M. ;

Troen, G. ;

Holte, H. ;

Kvaloy, S. ;

Dierickx, D. ;

Verhoef, G. ;

Delabie, J. ;

Smeland, E. B. ;

Jares, P. ;

Martinez, A. ;

Lopez-Guillermo, A. ;

Montserrat, E. ;

Campo, E. ;

Braziel, R. M. ;

Miller, T. P. ;

Rimsza, L. M. ;

Cook, J. R. ;

Pohlman, B. ;

Sweetenham, J. ;

Tubbs, R. R. ;

Fisher, R. I. ;

Hartmann, E. ;

Rosenwald, A. ;

Ott, G. ;

Muller-Hermelink, H. -K ;

Wrench, D. ;

Lister, T. A. ;

Jaffe, E. S. ;

Wilson, W. H. ;

Chan, W. C. ;

Staudt, L. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (22) :2313-2323

[6]

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60) [J].

Pfreundschuh, Michael ;

Schubert, Joerg ;

Ziepert, Marita ;

Schmits, Rudolf ;

Mohren, Martin ;

Lengfelder, Eva ;

Reiser, Marcel ;

Nickenig, Christina ;

Clemens, Michael ;

Peter, Norma ;

Bokemeyer, Carsten ;

Eimermacher, Hartmut ;

Ho, Anthony ;

Hoffmann, Martin ;

Mertelsmann, Roland ;

Truemper, Lorenz ;

Balleisen, Leopold ;

Liersch, Ruediger ;

Metzner, Bernd ;

Hartmann, Frank ;

Glass, Bertram ;

Poeschel, Viola ;

Schmitz, Norbert ;

Ruebe, Christian ;

Feller, Alfred C. ;

Loeffler, Markus .

LANCET ONCOLOGY, 2008, 9 (02) :105-116

[7]

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group [J].

Pfreundschuh, Michael ;

Trumper, Lorenz ;

Osterborg, Anders ;

Pettengell, Ruth ;

Trneny, Marek ;

Imrie, Kevin ;

Ma, David ;

Gill, Devinder ;

Walewski, Jan ;

Zinzani, Pier-Luigi ;

Stahel, Rolf ;

Kvaloy, Stein ;

Shpilberg, Ofer ;

Jaeger, Ulrich ;

Hansen, Mads ;

Lehtinen, Tuula ;

Lopez-Guillermo, Armando ;

Corrado, Claudia ;

Scheliga, Adriana ;

Milpied, Noel ;

Mendila, Myriam ;

Rashford, Michelle ;

Kuhnt, Evelyn ;

Loeffler, Markus .

LANCET ONCOLOGY, 2006, 7 (05) :379-391

[8]

AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA [J].

PHILIP, T ;

GUGLIELMI, C ;

HAGENBEEK, A ;

SOMERS, R ;

VANDERLELIE, H ;

BRON, D ;

SONNEVELD, P ;

GISSELBRECHT, C ;

CAHN, JY ;

HAROUSSEAU, JL ;

COIFFIER, B ;

BIRON, P ;

MANDELLI, F ;

CHAUVIN, F .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) :1540-1545

[9]

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy [J].

Savage, Kerry J. ;

Johnson, Nathalie A. ;

Ben-Neriah, Susana ;

Connors, Joseph M. ;

Sehn, Laurie H. ;

Farinha, Pedro ;

Horsman, Douglas E. ;

Gascoyne, Randy D. .

BLOOD, 2009, 114 (17) :3533-3537

[10]

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia [J].

Sehn, LH ;

Donaldson, J ;

Chhanabhai, M ;

Fitzgerald, C ;

Gill, K ;

Klasa, R ;

MacPherson, N ;

O'Reilly, S ;

Spinelli, JJ ;

Sutherland, J ;

Wilson, KS ;

Gascoyne, RD ;

Connors, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5027-5033

← 1 2 →